Company Overview
Axsome Therapeutics, Inc. operates as a biopharmaceutical company dedicated to developing and delivering novel therapies for the management of central nervous system disorders within the United States. The company functions within the broader healthcare sector, specifically categorized under the biotechnology industry, which implies a focus on early-stage innovation and high-risk, high-reward product development cycles. The organization employs 925 individuals and holds a market capitalization of $8.13B, while reporting a trailing twelve-month revenue of $638.50M. These valuation and revenue figures indicate that Axsome has transitioned from a purely speculative biotech entity to a commercial-stage company with a substantial market presence, supported by a significant workforce capable of driving its commercial portfolio, which includes Auvelity.
Financial Health
Axsome Therapeutics reported a revenue of $638.50M for the trailing twelve months, yet this top-line growth masks a net income of -$183,174,000 and an EBITDA of -$160,171,008. The substantial gap between the $638.50M revenue and the negative net income reveals a cost structure characterized by high operating expenses relative to current sales, a common trait in biotechnology firms scaling commercial operations. The company generated a free cash flow of -$29,420,876, indicating that it is currently consuming cash rather than generating excess liquidity, which limits immediate financial flexibility for large-scale acquisitions or aggressive share buybacks. Profitability is further strained by a gross margin of 92.6%, an operating margin of -18.4%, and a profit margin of -28.7%, where the wide disparity between the high gross margin and negative operating/profit margins highlights significant selling, general, and administrative costs or research and development expenditures. On the balance sheet, the company holds $322.93M in cash against $218.11M in debt, resulting in a debt-to-equity ratio of 247.03, which suggests a highly leveraged capital structure relative to its equity base. Despite the high debt-to-equity figure, the current ratio stands at 1.55, indicating that the company maintains sufficient current assets to cover its short-term liabilities. Return on Equity is recorded at -252.1% and Return on Assets at -16.8%, metrics that reveal that management is currently utilizing the company's equity and assets to generate losses rather than returns, reflecting the capital-intensive nature of the biotechnology business model.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is 27.57, a discrepancy that implies the market is pricing in significant future earnings growth expected to turn the company profitable in the coming fiscal periods. The price-to-book ratio is 91.57, a figure that indicates a substantial market premium over the company's book value, suggesting investors are willing to pay a high multiple for the company's intellectual property and future pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 12.73 and an EV/EBITDA of -50.09 suggest that the stock is valued primarily on revenue generation and sales pipeline rather than current cash flow or profitability. In terms of trading range, the stock has a 52-week high of $191.50 and a 52-week low of $86.99, and without a specific current price provided in the source data, the valuation relative to this range cannot be precisely calculated, though the forward P/E implies an expectation of movement away from the current depressed valuation levels. The beta value is 0.49, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting a defensive characteristic often associated with large-cap biotechnology firms or stocks with stable revenue streams despite earnings volatility.
Growth & Income
The company demonstrated a revenue growth rate of 65.0% year-over-year, while earnings growth is listed as N/A due to the absence of positive net income, implying that top-line expansion is currently outpacing any potential for profit generation. As a non-dividend payer, Axsome maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings and retained cash into research, development, and commercial expansion rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies in the growth phase, where capital allocation toward the central nervous system disorder portfolio is prioritized over income generation. The overall growth and income profile reflects a high-growth, zero-income trajectory where the primary financial metric of interest is the trajectory of revenue expansion and the eventual path to profitability rather than current shareholder yield.